| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 6.097 | 2.227 | 2.207 | 5.130 | 9.096 | 8.911 | 9.248 | 10.846 | 11.447 | 11.740 |
| Total Income - EUR | 6.097 | 2.227 | 2.207 | 5.144 | 9.096 | 8.911 | 11.224 | 11.819 | 14.101 | 12.142 |
| Total Expenses - EUR | 17.308 | 12.010 | 7.796 | 4.750 | 6.186 | 4.276 | 8.866 | 9.632 | 12.437 | 7.875 |
| Gross Profit/Loss - EUR | -11.212 | -9.783 | -5.589 | 394 | 2.910 | 4.635 | 2.358 | 2.188 | 1.664 | 4.267 |
| Net Profit/Loss - EUR | -11.394 | -9.850 | -5.656 | 239 | 2.637 | 4.367 | 2.114 | 1.885 | 1.367 | 3.632 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Elite Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 110.868 | 108.038 | 102.094 | 99.180 | 93.161 | 80.681 | 78.920 | 86.046 | 84.830 | 89.477 |
| Current Assets | 16.859 | 4.965 | 4.361 | 5.804 | 3.159 | 6.171 | 5.826 | 3.093 | 5.568 | 5.077 |
| Inventories | 181 | 0 | 0 | 968 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 3.988 | 4.168 | 3.775 | 3.137 | 1.767 | 926 | 91 | 312 | 195 | 194 |
| Cash | 12.690 | 797 | 586 | 1.699 | 1.391 | 5.245 | 5.736 | 2.781 | 5.373 | 4.883 |
| Shareholders Funds | 116.994 | 105.951 | 95.482 | 93.969 | 91.422 | 84.234 | 84.480 | 84.935 | 86.045 | 89.196 |
| Social Capital | 67 | 67 | 66 | 64 | 63 | 62 | 61 | 61 | 61 | 60 |
| Debts | 10.732 | 7.052 | 10.972 | 11.015 | 4.899 | 2.618 | 266 | 4.203 | 4.353 | 5.358 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Elite Pharma Srl